GSK US sales for the quarter just under $US26m (16m pounds)
http://www.gsk.com/investors/reports/q12012/q12012_statutory.pdf
According to their report:
"Arixtra sales declined 34% as a result of generic
competition in the US which began in Q3 2011."
(see http://www.gsk.com/investors/reports/q12012/q12012.pdf)
Can anyone estimate whether this is below or on par with expectations based on their dropping market share expectations?
I cannot find any ref to the Apotex Fonda (AG) figures - surely they should be incorporated into the figures somewhere - maybe they are part of the above?
I'm keenly awaiting the DR figures!!!
- Forums
- ASX - By Stock
- gsk arixtra sales
GSK US sales for the quarter just under $US26m (16m...
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable